July 12, 2021
Virtual 1×1 Webinar with Epigenomics AG (ECX.DE, EPGNF)
Podcasts
Virtual 1×1 Webinar with Epigenomics AG (ECX.DE, EPGNF) Listen
July 12, 2021
Key Opinion Leader Conference Call with Dr. Jonathan Zager, Principal Investigator for Delcath System’s Phase 3 FOCUS Study
Podcasts
Key Opinion Leader Conference Call with Dr. Jonathan Zager, Principal Investigator for Delcath System’s Phase 3 FOCUS Study. Listen Download the transcript
July 12, 2021
Essa Pharma
Archived Files
We believe Big Pharma’s familiarity with AR antagonism makes Essa a legitimate M&A candidate. Read More.
June 7, 2021
Modular Medical
Coverage Universe
As the company “Pivots” from development to commercial stage, we believe shareholders could reap outsized returns. Read More.
March 7, 2021
March 7, 2021 Update
Coverage Updates
We thought it timely to provide an update on our coverage universe. Many of our names have imminent catalysts that warrant investors’ attention. We also have two names that we […]
February 22, 2021
Processa Pharma
Coverage Universe
We believe by 2023, Processa could have one, or more, programs in Ph3, warranting a substantial bump in valuation, which we estimate to be >$500mm. Read More.
November 9, 2020
Ocuphire Pharma
Coverage Universe
Low Science / High Science, Low Risk / High Risk, Ocuphire has a little of everything, heading into a data-rich 2021. Read More.
October 21, 2020
Perimeter Medical
Coverage Universe
We believe Perimeter’s widefield OCT unit, OTIS, can be a solution to the reexcision “epidemic” in breast conservation surgery. Read More.
July 26, 2020
July 26, 2020 Update
Coverage Updates
Since our last update note in January, we have initiated on three new companies; TLC (Nasdaq: TLC), Delcath Systems (Nasdaq: DCTH), and Epigenomics (FSE: ECX.DE, OTC: EPGNF). This brings our […]
June 17, 2020
Epigenomics AG
Archived Files
We believe there is tremendous upside for investors by owning Epigenomics ahead of, what we expect to be, a positive CMS reimbursement decision by August 28th. Read more.